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Abstract
Background: Artemisinin combination therapy is recommended as first-line treatment for falciparum malaria across
the endemic world and is increasingly relied upon for treating vivax malaria where chloroquine is failing. Artemisinin
resistance was first detected in western Cambodia in 2007, and is now confirmed in the Greater Mekong region, raising
the spectre of a malaria resurgence that could undo a decade of progress in control, and threaten the feasibility of
elimination. The magnitude of this threat has not been quantified.
Methods: This analysis compares the health and economic consequences of two future scenarios occurring once
artemisinin-based treatments are available with high coverage. In the first scenario, artemisinin combination therapy
(ACT) is largely effective in the management of uncomplicated malaria and severe malaria is treated with artesunate,
while in the second scenario ACT are failing at a rate of 30%, and treatment of severe malaria reverts to quinine. The
model is applied to all malaria-endemic countries using their specific estimates for malaria incidence, transmission
intensity and GDP. The model describes the direct medical costs for repeated diagnosis and retreatment of clinical
failures as well as admission costs for severe malaria. For productivity losses, the conservative friction costing method is
used, which assumes a limited economic impact for individuals that are no longer economically active until they are
replaced from the unemployment pool.
Results: Using conservative assumptions and parameter estimates, the model projects an excess of 116,000 deaths
annually in the scenario of widespread artemisinin resistance. The predicted medical costs for retreatment of clinical
failures and for management of severe malaria exceed US$32 million per year. Productivity losses resulting from excess
morbidity and mortality were estimated at US$385 million for each year during which failing ACT remained in use as
first-line treatment.
Conclusions: These ‘ballpark’ figures for the magnitude of the health and economic threat posed by artemisinin
resistance add weight to the call for urgent action to detect the emergence of resistance as early as possible and
contain its spread from known locations in the Mekong region to elsewhere in the endemic world.
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Background
The past decade has seen substantial progress in malaria
control, with local elimination now a feasible objective in
parts of the Asia-Pacific, Middle East, Latin America and
even in some areas of sub-Saharan Africa (SSA). Much of
this progress has been ascribed to the increasing availabil-
ity of artemisinin compounds, with their rapid clearance
of asexual blood stage parasitaemia and gametocytocidal
properties that curb transmission to other individuals
[1,2]. Artemisinin-based combination therapy (ACT) is
the recommended first-line treatment for uncomplicated
falciparum malaria across almost the entire endemic
world, and large investments are being made to extend
coverage in both the public and private sectors. For severe
malaria, the recent change in recommended treatment
from quinine to artesunate offers an approximately 25%
greater chance of survival [3,4] although uptake in en-
demic areas has been slow.
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The loss of artemisinin efficacy would therefore
threaten these real and potential gains, and historical
precedent, clinical, laboratory, and modelling work all
suggest that artemisinin compounds could lose their ef-
ficacy long before elimination is a realistic aim in high
transmission areas [4-9].
Evidence to suggest emergence and/or spread of artemi-
sinin resistance is amassing. Early warning signs in the
form of slowing parasite clearance times in western
Cambodia were detected in 2007 and soon after along the
Thai-Burmese border [5,10,11]. There is now evidence of
artemisinin resistance in Plasmodium falciparum in five
countries in the Greater Mekong region [12]. The recent
identification of Kelch mutations associated with artemisi-
nin resistance on chromosome 13 is likely to better specify
just how far it has already spread [13].
In ACT, the loss of artemisinin efficacy would expose
partner drugs to greater selection pressure for the devel-
opment of resistance, compromising the effectiveness of
the combination. There is currently no good alternative
to ACT suitable for large-scale implementation. New
drugs will surely be developed but the lag time between
development, registration, change of national treatment
policy, training, and large-scale production imply an in-
evitable and costly delay until affordable substitutes to
ACT are widely available. For severe malaria the spread
of resistance will likely result in reverting to or maintain-
ing quinine as the treatment of choice, and therefore the
loss of the real or potential gain offered by artesunate.
The following analysis is a modelled snapshot of two
contrasting future scenarios following extensive adop-
tion of ACT. In the first, artemisinins maintain high
levels of efficacy with ACT cure rates of 95% and where
artesunate is used to treat severe malaria. In the second
scenario, artemisinins face widespread resistance, leading
to ACT clinical failure rates of 30% and where policy has
reverted to quinine to manage severe malaria. This is
not a prediction of how artemisinin resistance is likely to
spread and result in clinical failure of ACT, or the inter-
action with changing malaria transmission. Rather, the
aim here is to estimate the magnitude of the threat
posed by artemisinin resistance should this result in in-
creasing ACT failures and the loss of artesunate’s advan-
tage in treating severe malaria.
Methods
The excess mortality associated with artemisinin resist-
ance is a product of: i) an increased proportion of ACT
failures in uncomplicated malaria, a proportion of which
become severe; and, ii) patients with severe malaria who
are treated with quinine instead of artesunate [4]. The
economic costs comprise of additional diagnostic tests
and ACT for treatment failures, the cost of treating a
higher number of severe malaria cases, and the cost of
switching policy to alternative ACT or other first-line
therapy once these are available. Productivity losses asso-
ciated with the excess morbidity and mortality are also
estimated.
Baseline and resistance scenarios
This analysis compares a baseline scenario characterized
by an ACT failure rate of 5% against a scenario of 30%
ACT failure rate, a conservative estimate compared with
the fate of previous first-line treatments [14] and with a
recent study from the northwestern border of Thailand,
an area where artemisinin resistance is established, where
the failure rate for artesunate-mefloquine in the treatment
of Plasmodium falciparum was 58% [10]. Severe malaria
cases that access inpatient care are assumed to receive
artesunate in the baseline scenario and quinine in the sce-
nario of artemisinin resistance. The excess impact is calcu-
lated by subtracting the total mortality and costs of the
baseline scenario from those of the resistance scenario.
ACT coverage is assumed to be complete in both future
scenarios, as is artesunate coverage for severe malaria in
the baseline scenario.
Model structure and parameter estimates
A decision tree was used to model the outcomes of the two
scenarios (Figure 1). The model is applied to each malaria-
endemic country with outputs being aggregated by region.
The WHO estimates for country-level incidence of pre-
sumed and confirmed malaria cases from the 2013 World
Malaria Report were used as these are conservative esti-
mates that include cases that are most likely to receive an
ACT, as opposed to other estimates that include undocu-
mented cases, which by definition are seeking care outside
of the formal health sector. The number of cases was modi-
fied by the proportion of falciparum cases from the same
report. The model then divides patients between low and
high transmission settings, using country-specific data, with
implications for population immunity and subsequent mor-
tality rates.
The model subdivides the cases into treatments that
were effective and those that fail; in the baseline scenario
a failure rate of 5% is assumed [14] while in the resistance
scenario a conservative estimate of 30% is used. A small
proportion of treatment failures deteriorate to severe ill-
ness with a point estimate of 2%. This is derived from an
artesunate efficacy study for uncomplicated malaria in
areas of Cambodia where resistance is believed to be high,
where 3/159 patients developed severe illness [15]. A pro-
portion of severe cases are able to access inpatient care; in
the absence of relevant data, a range of estimates from 40
to 90% were used, determined by a log function of the
countries’ GDP per capita. For patients without access to
care, a high mortality rate of 50 and 70% was assumed in
high- and low-transmission settings [16]. For patients who
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access health facilities, an assumption is made that in the
baseline scenario first-line treatment is artesunate with a
mortality rate of 8.5 and 15% in high- and low-transmission
settings, respectively. In the scenario of artemisinin resist-
ance, it is assumed that severe malaria would be treated
with quinine [14], associated with a mortality of 10.9% in
high-transmission areas and 22% in other regions [3,4].
Direct medical costs, policy-changing costs and
productivity losses
The excess cost of a treatment failure that does not progress
to severe illness was estimated as the cost of an additional
diagnostic test and a second ACT (again, assuming full
coverage). A lower unit cost per ACT of 0.8 US$ in applied
to the high-transmission setting where most patients will be
young children and 1.6 US$ per ACT in the low-
transmission setting where most patients are adults, and a
cost of 0.8 US$ per rapid diagnostic test [17]. The cost of in-
patient care for severe malaria was estimated at 65 US$ [18].
The introduction of a new first-line therapy, once avail-
able, will require policy changes with supporting and
training programmes to facilitate its deployment. Mulligan
et al. conducted the only detailed estimate for the costs of
a national revision of anti-malarial treatment guidelines,
for Tanzania in 2002 [19]. These costs include retraining
and education programmes but not the incremental costs
of newer drugs, which by historical precedent would ex-
ceed those of their predecessors. After inflationary adjust-
ments and classification as either fixed or variable costs,
the latter assumed to be correlated with population size,
these findings were applied to other malaria-endemic
countries.
Productivity losses are estimated using GDP per capita
for each country [20]. Productivity losses due to excess
morbidity are calculated using an estimate of one week of
lost earnings due to a case of uncomplicated malaria [21],
an additional week of productivity lost to treatment failure,
and an assumed three weeks of lost productivity due to se-
vere malaria. Productivity losses for mortality are equated
to those of severe illness, adopting the rationale of the fric-
tion cost methodology that assumes only a short-term im-
pact on productivity, with an unemployment reservoir
mitigating a longer term economic impact [22]. This is a
conservative methodology as compared with the more
widely used human capital approach that equates product-
ivity losses with life-long lost earnings, as this has been cri-
ticised for inflating the actual economic impact [23].
Costs are expressed in 2013 USD. Where adjustments
were necessary we used the World Bank consumer price
index and exchange rates to adjust costs from local units
to 2013 USD.
Sensitivity analysis
A probabilistic sensitivity analysis was carried out to
generate results using distributions for the probability of
treatment failures becoming severely ill and for the mor-
tality rates for treated and untreated severe malaria
(shown in Table 1), with 1,000 random samples drawn
from each distribution and for each country. The mean
mortality and costs for each scenario were used to ob-
tain the point estimates and the values at the 2.5 and
97.5% quintiles for the uncertainty intervals.
The sensitivity of results to individual parameters was
tested by varying their values within plausible ranges
(shown in Table 1) while holding other parameters at
their initial estimates. The impact of the most influential
parameters were summarized in a Tornado diagram and
in two-way sensitivity analyses. As model parameters are
specific to each region or country, the sensitivity ana-
lyses focussed on SSA where the burden of malaria and
the impact of artemisinin resistance would be highest.
The primary analysis assumes full ACT coverage. Lower
coverage of ACT would imply a lesser potential impact of
widespread resistance (but lesser gains due to ACT in the
baseline scenario in the first place). The other assumption
used in constructing the scenarios was a clinical failure rate
in ACT of 30% in the presence of widespread artemisinin
resistance. The impact of using different assumptions in
Figure 1 Decision tree model of the human and economic consequences of artemisinin-combination therapy malaria treatment failure.
The decision tree diagram illustrates how malaria incidence, deaths and costs are calculated in each of the two scenarios. The top branch
represents the scenarios in which artemisinins are effective. This structure is replicated in the bottom branch representing the scenario of
artemisinin resistance, with the necessary adjustments to parameter values. The branch following the blue node at High transmission is also
replicated with parameter adjustments at the Low transmission node.
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Table 1 Parameter estimates, ranges and sources
Parameter Base case Range/distribution Comments Source
Probabilities for clinical parameters
ACT failure rate in a scenario of widespread resistance (P2) 30% 30-80% A conservative estimate as compared with recent ACT failure rates
in Mae Sot, Thailand and those for chloroquine, amodiaquine and
sulphadoxine-pyrimethamine
in SSA and Asia.
Assumption [10,14]
ACT failure rates in the absence of widespread resistance (P2) 5% 0-10% [14]
Treatment failure becomes severe (P3) 2% 0.5-5% Data from an artesunate efficacy trial in Cambodia and best fit to
WHO incidence/mortality data
[15,24]
Beta distribution
(α = 3 β = 156)
Mortality rate for severe malaria treated with quinine – Asia, EM, LA 22% Beta distribution A large multisite in Asia (the trial data were also used to construct
the probability distributions for the PSA)
[3]
(α = 164 β = 567)
Mortality rate for severe malaria treated with artesunate – Asia, EM, LA (P5) 15% Beta distribution [3]
(α = 107 β = 627)
Mortality rate for severe malaria treated with quinine – SSA (P5) 10.9% Beta distribution The largest study of severe malaria treatments in hospitalized patients [4]
(α = 297 β = 2,416)
Mortality rate for severe malaria treated with artesunate – SSA (P5) 8.5% Beta distribution [4]
(α = 230 β = 2,482)
Mortality rate for untreated severe malaria – high transmission (P6) 50% 40-90% [16,24]
Beta distribution
(α = 5 β = 5)
Mortality rate for untreated severe malaria – low transmission (P6) 75% 40-90% [16,24]
Beta distribution
(α = 7 β = 3)
Access to care
Access to any anti-malarial (P1) 20-100% Country level data [24-27]
Access to inpatient care (P4) 40-90% Determined by GDP per capita
Costs
ACT $0.8/$1.6 Private sector prices are mostly higher which would imply higher
costs for retreatment of failures
[28]
Test $0.8 $0.5-1.5 [24]
Inpatient care for severe malaria $65 [18]
SSA – sub-Saharan Africa; LA – Latin America; EM – Eastern Mediterranean; SEA – Southeast Asia; WP – Western Pacific.
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defining the scenario of artemisinin resistance was explored,
assuming that in the absence of an ACT the coverage of
anti-malarials is similar to current best estimates (using the
most recent country specific data from DHS surveys [29])
and with an efficacy in non-artemisinin-based anti-malarials
of 35%, a higher estimate than the data for most non-
artemisinin anti-malarials would suggest [13].
The model was developed using TreeAge Pro (Tree-
Age Software Inc, Williamstown, MA, USA) and results
were graphed using Microsoft Excel and mapped in
Google Maps.
Results
If malaria incidence was to remain similar to current
levels, the model estimates the excess number of treat-
ment failures in the scenario of widespread artemisinin re-
sistance to approximate 22 million annually, until an
effective alternative anti-malarial is deployed. These would
lead to 230,000 additional severe malaria cases (surviving)
and 116,000 excess deaths per year. Excess malaria mor-
tality estimates by country are presented in Figure 2 and
the annual mortality in each scenario by region in Figure 3,
as well as the 95% uncertainty interval for these from the
probabilistic sensitivity analysis.
Approximately 77% of these deaths would result from
the excess number of ACT treatment failures in the sce-
nario of artemisinin resistance, while the remaining 23%
are due to the use of quinine instead of artesunate for
the management of severe malaria.
The direct medical costs for malaria treatments in the
baseline scenario would be 114 million US$ (111–117 mil-
lion US$), while in the scenario of ACT resistance this
would be 28% higher at 146 million US$ (134–167 million
US$). The cost of policy change across the endemic world is
estimated at 130 million US$. This cost would be borne re-
peatedly if switching between ACT as and when resistance
to the partner drug emerged, and once an alternative non-
artemisinin-based class of drug is deployable.
The model estimates productivity losses due to excess
morbidity and mortality at 385 million US$ when using
the conservative friction cost methodology (regional break
down shown in Figure 4). Approximately 90% of this cost
is due to productivity losses associated with excess mor-
bidity following treatment failures. Country-specific model
outputs for mortality and costs in each of the two scenar-
ios are available on the interactive map online [30].
Sensitivity analysis
A large number of parameters were influential in determin-
ing the excess mortality, most importantly the probability
of treatment failures becoming severe, the incidence of mal-
aria cases, and the mortality rate in severe malaria treated
with quinine (Figure 5). The probability of treatment fail-
ures becoming severely ill was particularly influential with a
range of 0.5 to 5% corresponding to excess deaths ranging
from 25,000 to over 300,000. Similar influences are ob-
served in the excess costs as these are a product of the ex-
cess clinical failures, severe cases and deaths.
Figure 6 shows the impact of varying the ACT coverage
and their effectiveness in the scenario of artemisinin re-
sistance. With the lowest estimate for efficacy of 30% (still
exceeding that for widely used non-artemisinin treatments
in many endemic areas), the mortality estimate for SSA
rises to approximately 300,000. If, however, the coverage
of ACT remains restricted to 40% of cases, the impact of
artemisinin resistance will range between approximately
35,000 and 130,000 excess deaths, depending on the esti-
mate for failure rates.
Discussion
This analysis does not project how artemisinin resistance
is likely to spread or portray the most probable scenario
Figure 2 Excess mortality due to artemisinin and artemisinin-combination therapy resistance in malaria-endemic areas. The map shows
the model output for estimated excess mortality in the scenario of artemisinin resistance. Individual country estimates for this and other model
outputs are available online [30].
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that is likely to unfold. Rather, this is a crude assess-
ment of the threat posed by artemisinin resistance in
the event that efficacy drops to 70%, which would re-
main more efficacious than most previous first-line
anti-malarials once resistance to these emerged. Many
key parameter estimates are uncertain, although the
methods and point estimates chosen were conservative.
The scope of cost elements and economic impacts in-
cluded was also limited. Household costs due to mal-
aria were excluded although these have been shown to
be substantial [31] and are also likely to increase with
ineffective treatments. Artemisinin resistance is likely
to threaten elimination strategies, allowing malaria to
continue its demonstrated drain on macro-economic
growth [32,33]. Re-introduction of malaria to areas that have
recently eliminated is also more likely with loss of effective
treatment and costly surveillance systems will be required as
long as this remains a possibility. Inclusion of these factors
would imply greater health and economic costs than those
described above.
Figure 3 Annual malaria mortality in each of the two scenarios. Malaria mortality in each of the two scenarios by region. SSA – sub-Saharan
Africa; LA – Latin America; EM – Eastern Mediterranean; SEA – Southeast Asia; WP – Western Pacific.
Figure 4 Productivity losses due to artemisinin resistance. These values represent the productivity losses each year in the scenario of
widespread resistance using the conservative friction cost method.
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The analysis considered homogenous ACT failure rates
across the endemic world, but which areas are most likely
to be affected? While the projected burden in this analysis
is greatest in Africa, there is no evidence to date that resist-
ance has spread there. Countries in closer proximity to the
known epicentre, such as Myanmar, Bangladesh and India
with large populations at risk of unstable P falciparum
transmission, face a more imminent threat. Asian areas of
low transmission with high drug pressure continue to pro-
vide fertile breeding ground for the emergence and spread
of drug resistance. Use of artemisinin monotherapy was
widespread in much of the region and substandard
artemisinin-based treatments are also prevalent [34,35]. For
these reasons resistance to all previous anti-malarials was
documented initially in Southeast Asia, which was followed
by its spread to Africa where the impact was most detrimen-
tal. Greater population movement could further facilitate
the spread of artemisinin resistance as compared with previ-
ous anti-malarials. Increasing migration between China and
Africa, for instance, could facilitate transmission of resistant
parasites between these regions [36].
There are extensive limitations to this analysis relating
to both the model structure and parameter estimates.
The model’s static structure compares two distinct scenar-
ios – ACT being effective to a homogenous 30% failure rate
for all ACT across the endemic world. In reality the spread
Figure 5 The sensitivity of projected excess deaths in sub-Saharan Africa to key input parameters. The graph illustrates the relative
impact of different parameters on model outputs. A key parameter is the probability of patients with a treatment failure becoming severely ill. A
higher estimate of 5% implies a large increase in the total excess mortality in SSA to over 300,000 deaths per year. Another influential parameter
is the treatment failure rate for ACT in the scenario of widespread resistance. If clinical failure rates were to resemble those documented in many
previously used antimalarials the excess mortality would be far higher.
Figure 6 Excess mortality in sub-Saharan Africa in the scenario of artemisinin resistance across varying levels of artemisinin-combination
therapy coverage and efficacy rates for artemisinin-combination therapy in the resistance scenario. Lower coverage of ACT would imply a
lesser impact in the scenario of artemisinin resistance (and conversely lower potential benefit in the scenario of effective artemisinins). Varying the
degree of ACT efficacy in the scenario of artemisinin resistance would have a large impact on results.
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and impact of artemisinin resistance followed by ACT re-
sistance, should it occur, will be extremely heterogeneous
and dependent on transmission intensity, coverage, partner
drug mutation rates, health system preparedness, and many
other variables. Containment measures could mitigate the
spread of resistance. It might be possible, for instance, to
‘buy time’ by extending the regimen of ACTs to maintain
high cure rates. Alternatively other ACT with new partner
drugs could be introduced if existing ones fail, mitigating
some of the potential impact but incurring the cost of pol-
icy change and likely higher drug costs. Exclusion of these
factors from the analysis is an over-simplification but is
nevertheless consistent with the aim of quantifying the cost
of widespread artemisinin and ACT resistance should this
occur. Some key parameter estimates are lacking robust
supporting evidence, most importantly the probability of be-
coming severely ill following treatment failure for which we
used a single study with patients treated with artesunate.
Critically, the model assumes that the incidence of mal-
aria in both scenarios will resemble current levels. For the
annual incidence, the number of probable and confirmed
malaria cases in the 2013 World Malaria Report was used.
These are at the lower end of current estimates [24,37]
and do not account for many undocumented cases, but
this is more consistent with the assumption of high future
ACT coverage, as these cases will have been appropriately
diagnosed, treated and documented. In addition to the ex-
tensive uncertainty surrounding incidence for previous
years, projections of future trends are challenging, with
transmission being influenced by the availability of ACT
and other interventions, as well as a range of factors
including economic, environmental and demographic
change. The spread of artemisinin and ACT resistance will
itself be a product as well as a cause of change in trans-
mission. A global malaria transmission model accounting
for all these factors required to predict the spread of arte-
misinin resistance has not yet been successfully created.
Conclusion
This analysis, albeit dependent on many strong assump-
tions, provides a set of conservatively estimated ‘ballpark’
figures for the excess mortality and economic losses that
would follow widespread resistance to artemisinin-based
therapy. These figures in themselves cannot be used to
identify the optimal levels of investment that would be
justified to contain artemisinin resistance, as this would
require further estimates for the probability that a scenario
such as this will unfold and the potential effectiveness of
containment strategies. The magnitude of the threat, how-
ever, suggests that even if this is a remote possibility, con-
siderably greater attention and investment in delaying or
eliminating its possible emergence than are currently being
provided are justified. There may be only a limited window
of opportunity to contain and eliminate this imminent
global threat.
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